A Clinical Trial to Evaluate Efficacy and Safety of a New Suffocating Head Lice Product.

NCT05378477 | Unknown DMC FDA Device

• 1 other identifier: OYS008-0020
• Study Type: interventional
• Target: 220
• Locations: 1 country
• Sites: 1

Brief Summary

The present study is set-up to compare in vivo clinical performance and safety of the test product (X92001752) versus 3 other pediculicides (2 medical devices and 1 conventional pesticide).

Conditions

Head Lice; Pediculosis Capitis

Outcome Measures

Primary Outcomes (1)

• Number of Subjects That Are Lice-free After 2 Treatments With Test Product (Including All Baseline Infestations).

  Clinical efficacy is reflected by the % of subjects that are lice-free after 2 topical applications (at day 0 \& day 7 respectively) of the test product. In this analysis, all baseline infestations (mild, moderate, severe) have been included. Assessment is performed at study end (visit 4, day 10). A mild infestation corresponds to 5-9 lice and/or nymphs A moderate infestation corresponds to 10-24 lice and/or nymphs A severe infestation corresponds to 25 or more lice and/or nymphs

  Day 10

Secondary Outcomes (11)

• Number of Subjects That Are Lice-free After 2 Treatments With RID Super Max Solution (Including All Baseline Infestations).

  Day 10

• Number of Subjects That Are Lice-free After 2 Treatments With Nix crème (Including All Baseline Infestations).

  Day 10

• Number of Subjects That Are Lice-free After 1 Treatment With Pouxit Végétal (Including All Baseline Infestations).

  Day 10

• Effect of All Investigational Treatments on Pruritus (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.

  Day 0, Day 1, Day 7, Day 10

• Effect of All Investigational Treatments on Scalp Excoriation (Local Tolerability Parameter), as Assessed by a Blinded Clinical Investigator.

  Day 0, Day 1, Day 7, Day 10

Study Arms (4)

Test product

EXPERIMENTAL

Hemisqualane \& beeswax-based lotion (X92001752), killing lice and nits via suffocation.

Device: X92001752

RID Super Max Solution

ACTIVE COMPARATOR

Oligodecene oil-based lotion, killing lice and nits via suffocation.

Device: RID Super Max Solution

Nix Crème

ACTIVE COMPARATOR

Conventional pesticide, containing 1% permethrin.

Drug: Nix Crème

Pouxit Végétal

ACTIVE COMPARATOR

Fatty acid salt-based lotion, killing lice and nits via suffocation.

Device: Pouxit Végétal

Interventions

X92001752 DEVICE

The test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.

Also known as: Test product

Test product

RID Super Max Solution DEVICE

RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.

Also known as: Reference product 1

RID Super Max Solution

Nix Crème DRUG

Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7.

Also known as: Reference product 2

Nix Crème

Pouxit Végétal DEVICE

Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed.

Also known as: Reference product 3

Pouxit Végétal

Eligibility Criteria

• Age: 1 Year+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Gender: male / female.
• Women of childbearing potential is a premenopausal female that is anatomically and physiologically capable of becoming pregnant following menarche.
• Female subjects: are women of childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent during the study. Methods of contraception considered acceptable include oral contraceptives, contraceptive patch, intrauterine device, vaginal ring, diaphragm with contraceptive gel, or condom with contraceptive gel
• or are women of non-childbearing potential, defined as: women who have had surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation) or women who are ≥60 years of age.
• Age: ≥ 12 months of age year of age at the time of enrollment.
• Subject must have an active head lice infestation defined as at least 5 live lice (adults and/or nymphs) and 5 apparently live nits, present on the scalp and/or hair, as determined by a trained evaluator.
• Subject is in good general health based on medical history.
• The subject or his/her parent/legal guardian (from age 12-17), must give written informed consent, after having been oral and written informed about benefits and potential risks of the trial, as well as information regarding the insurance, taken out to cover the subjects participating in the study. A caregiver must sign an informed consent agreement for children not old enough to do so. Children ages 6-11 years of age will be administered a child's assent form. Subject or his/her parent/legal guardian must be capable of understanding and providing written informed consent.
• Following application and rinsing of the test products, subject agrees not to shampoo, wash, or rinse their hair or scalp until the 24-hour post treatment evaluation has been completed.
• The subject agrees not to cut or chemically treat their hair while participating in the study.
• No more than one working male per household may be excluded from evaluation if he is assessed as being lice free by himself or caregiver.
• Subject agrees to follow all study instructions, including attending all follow-up appointments.
• Agree to not use any other pediculicides or medicated hair grooming products for the duration of the study (through Day 10 visit).
• The parent or legal guardian of a child must be willing to have other family members screened for head lice. If other household members are found to have head lice and are eligible, they must be either enrolled in the study OR receive the standard of care at the site and in the same manner as study participants.
• Have a single place of residence.

You may not qualify if:

• \. Application of any form of head lice treatment, whether prescription or over-the-counter (OTC), or home remedy for 14 days prior to their screening visit (Visit 1).
• Application of any topical medication of any kind on the hair for a period of 48 hours prior to the screening visit.
• \. Use of systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results.
• \. Known skin allergies, multiple drug allergies or multiple allergies to cosmetic products.
• \. History of allergy or hypersensitivity to active ingredients, or constituents of the test products.
• \. Subject with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test product.
• \. Subjects with chronic scalp disorder. 8. Subject or his/her legal guardian who, in the opinion of the investigative personnel, do not understand the subject requirements for study participations and/or may be likely to exhibit poor compliance with the required visits.
• \. Females who are pregnant or nursing. 10. Hair longer than mid-back. 11. Subject suspected or known not to follow instructions 12. Previous participation in this study or participation in any other investigational trial within the preceding 14 days.
• \. The subject is directly affiliated to the investigator site personnel and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
• \. The subject is an Oystershell employee or is an employee of a third-party organizations involved in the study.

Sponsors & Collaborators

• Oystershell NV: lead

Study Sites (1)

South Fla. Family Health & Research Ctr.LLC

Plantation, Florida, 33186, United States

RECRUITING

Study Officials

• Susel Gonzalez Acosta, ARNP

  PI

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Elisabeth Rivera, CRD

CONTACT

305-387-0051; sffelisabeth@sffhrc.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 12, 2022
• First Posted: May 18, 2022
• Study Start: January 17, 2022
• Primary Completion: September 30, 2022
• Study Completion: September 30, 2022
• Last Updated: September 21, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)